Parasitic protozoan diseases continue to rank among the world's greatest global health problems, which are also common among poor populations. Currently available drugs for treatment present drawbacks, urging the need for more effective, safer, and cheaper drugs. Artemisinin (ART) and its derivatives are some of the most important classes of antimalarial agents originally derived from Artemisia annua L. However, besides the outstanding antimalarial and antischistosomal activities, ART and its derivatives also possess activities against other parasitic protozoa. In this paper we review the activities of ART and its derivatives against protozoan parasites in vitro and in vivo, including Leishmania spp., Trypanosoma spp., Toxoplasma gondii, Neospora caninum, Eimeria tenella, Acanthamoeba castellanii, Naegleria fowleri, Cryptosporidium parvum, Giardia lamblia, and Babesia spp. We conclude that ART and its derivatives may be good alternatives for treating other non-malarial protozoan infections in developing countries, although more studies are necessary before they can be applied clinically.
Introduction
The World Health Organization recognizes 17 major parasitic and related infections as neglected tropical diseases (NTDs) that affect many countries in Africa, Asia, and Latin America. However, the lack of commercial interest in developing new pharmaceutical compounds for combating these diseases has impaired efforts to eliminate them [1, 2] . Discovery of new, safe, effective, and affordable active drugs is thus urgently needed. Artemisinin (ART) and its derivatives are one of the most important classes of antimalarial drugs. Like many other natural sesquiterpenes, ART displays a range of different biological and pharmacological properties. Except for its antimalarial and antischistosomal activities, ART has also been shown to possess antimicrobial [3] and antiviral activities [4] . In addition, the antiparasitic function of ART against non-malarial parasites cannot be ignored. Here we screened the literature through extensive searches of PubMed, ResearchGate, Elsevier ScienceDirect, Wiley Online Library, and the Springer-Link Journals database using the search term "artemisinin" for publications in English with no date limits as well as through manual review of some related journals. We outline the use of ART and its derivatives in treating parasitic diseases or parasitic infections caused by protozoan parasites including Leishmania spp., Trypanosoma spp., Toxoplasma gondii, Neospora caninum, Eimeria tenella, Acanthamoeba castellanii, Naegleria fowleri, Cryptosporidium parvum, Giardia lamblia, and Babesia spp.; only drugs with activities against these protozoan parasites are reported. Studies have demonstrated good efficacies of ART and its derivatives in vivo and in vitro towards some of the parasitic protozoan infections. Clinical trials using different semisynthetic and synthetic ART derivatives should be undertaken to develop treatments for these parasitic diseases.
Chemical characteristics of ART and its derivatives
In 1967, under the instructions of Chairman Mao and Premier Zhou, a secret project called "Project 523" was launched to develop a new drug to combat drug-resistant malarial parasites [5, 6] . In 1971, Youyou Tu and her team isolated a new anti-malarial drug, called Qinghaosu (or ART), from Artemisia annua L. (Qinghao), which was shown to inhibit proliferation of Plasmodium parasites [6] .
ART and its derivatives share a common structural feature called endoperoxide linkage [7] . In general, ART has poor solubility in both water and oil. However, by reducing the C-10 carbonyl group of ART, a more water-soluble derivative dihydroartemisinin (DHA) can be obtained [5, 8] . Artesunate is the water-soluble hemisuccinate ester of DHA [9] . According to Chaturvedi et al., by adding a methyl or ethyl ethers at the same carbonyl group, higher oil soluble compounds like artemether and arteether were obtained [7] . Artemisone was obtained by replacing the same carbonyl with amines in the ART molecule, which showed improved water solubility, better toxicity profile, and a longer half-life [8] . Due to the short in vivo half-lives and low bioavailability of ART derivatives, arterolane and artefenomel (1, 2, 4-trioxolane analogues) were created to achieve more favourable pharmacokinetics. They were synthesized by coupling symmetrical O-methyl 2-adamantanone oxime with cyclohexanones by the Griesbaum co-ozonolysis [10] . Arterolane and artefenomel have longer half-lives compared to DHA, higher bioavailability than artemether, and are comparable to artesunate [11] . However, trioxolane-like arterolane has relatively low in vivo stability [8] ; that is why 1, 2, 4, 5-tetraoxanes with similar peroxide bridges, better stability, and more potent anti-malarial activity such as RKA 216 and RKA182 were developed [12] . In addition, deoxygenated artesunate (Deoxy-ATS), artemiside, synthetic trioxolanes (LC50, LC67, and LC95), and fluoro-artemisinin derivatives (BB200, BB201, BB241, and BB242) are proven to have anti-protozoal effects. The structures of ART and its derivatives included in this publication are shown in Fig. 1 .
ART and its derivatives on Leishmania spp.
Leishmaniasis affects approximately 350 million people in 98 countries around the world [13] . The disease manifests primarily as three forms, namely cutaneous leishmaniasis, mucocutaneous leishmaniasis, and visceral leishmaniasis, with the last being fatal if left untreated [14] . Current anti-leishmanial drugs include pentavalent antimony, amphotericin B, paromomycin, pentamidine, and miltefosine, with toxic effects to the liver, heart, and kidney, as well as anemia, fever, and hypokalemia. Therefore, usage is limited by their toxicity and adverse reactions [15, 16] . Miltefosine and paromomycin are two drugs that have been introduced more recently for the treatment of leishmaniasis [16] . However, long-term therapy with miltefosine's long half-life (about 152 h) can promote early onset of drug resistance, and potential teratogenic and abortifacient effects limit its prescription during pregnancy [17, 18] . Paromomycin is an aminoglycoside antibiotic that has shown promising results in the treatment of leishmaniasis, mainly for treating its cutaneous form [16] . However, in vitro tests have led to the emergence of paromomycin-resistant [19] , miltefosine-resistant [19] , meglumine antimoniate-resistant [20] , and pentamidine-resistant [21] parasites; therefore the therapy of visceral leishmaniasis is limited by resistance, toxicity, and decreased bioavailability of the existing anti-leishmanial agents [22] . The effects of ART and its derivatives on Leishmania parasites have been studied in mice and in vitro. They are efficient in inhibiting the parasite metabolism, while showing limited adverse effects on the host, indicating a higher safety index of the drugs [23, 24] . A large number of in vitro and in vivo studies have now shown that ART and its derivatives have activities in controlling Leishmania parasites; the drugs shown effective against the protozoan are selected and summarized in Table 1 . 
In vitro studies
ART works by impairing the activation of host macrophages, preventing the production of lethal nitric oxide (NO) and restoring normal NO production in L. major-infected macrophages [36] . Similar effects have been observed for the treatment of L. major, L. infantum, L. tropica, L. braziliensis, L. mexicana, and L. amazonensis [17, 28] . In addition, ART enables externalization of phosphatidylserine and leads to the loss of mitochondrial membrane potential, cell-cycle arrest at the sub-G0/G1 phase, and programmed cell death of L. donovani promastigotes [23] . Iron in excess binds to hemoglobin and activates ART by aiding the formation of intra-parasitic heme-iron, which catalyses the cleavage of the endoperoxide ring and enables the transfer of an oxygen atom from the peroxide group to a chelated iron ion, generating a Fe(IV)O species. The resultant free radical intermediate or iron-ART adduct then effectively kill the promastigotes of Leishmania parasites by alkylation [29] . ART showed high toxicity and apoptotic effect on promastigotes and low toxicity on BALB/c macrophages [25] . ART-derived trioxanes and synthetic trioxolanes were tested against promastigotes and intramacrophage amastigotes of L. infantum, in which trioxolanes LC50 and LC95 had the best activity and safety profiles, showing potential for leishmanial therapy [35] . Fluoro-artemisinin derivatives (BB200, BB201, BB241, and BB242) are proven to have higher efficacy than DHA and sitamaquine; especially BB201 was shown to have higher efficacy than miltefosine, DHA, and sitamaquine against the parasite [32] . ART [23, 25] , artemether [27, 28] , and the n-hexane fractions of Artemisia annua leaves (AAL) and seeds (AAS) [37] had anti-leishmanial effects in infected host cells. In another study, fluorophenyl-artemisinin was shown to have higher efficacy in inhibiting L. donovani in vitro growth than ART and artemisone, and comparable efficacy to amphotericin B [31] .
In vivo studies
Studies have shown that the leaves and seeds of A. annua caused increased production of Th1 cytokines [interferon-gamma (IFN-)] and decreased Th2 cytokines [interleukin (IL)-4 and IL-10] in L. donovani-infected BALB/c mice [30] . The anti-leishmanial activity of ART was mediated by increased IL-4 and IFN-levels in the host cells, inducing apoptotic effects on promastigotes and reducing post-treatment lesion size in L. major-infected BALB/c mice. In addition, using topical ART ointment as a route of administration, a higher healing effect compared to other routes of administration was achieved [25] . ART-loaded nanoparticles and combination therapy of diminazene and ART have a therapeutic effect comparable to that of the first-line drug amphotericin B, leading to significant reduction in hepatomegaly and parasite burden in L. donovani-infected BALB/c mice [24, 30] .
Human trial
The only clinical study presently available failed to show a significant difference between the artesunate plus sulfamethoxypyrazine/pyrimethamine treatment and the placebo [38] .
ART and its derivatives on Trypanosome spp.
There are two distinct species of Trypanosome in humans: Trypanosoma brucei causes African trypanosomiasis or African sleeping sickness and T. cruzi causes American trypanosomiasis or Chagas' disease [39] . The only drugs now available for Chagas disease, nifurtimox and benznidazole, are relatively toxic for adult patients, and require prolonged administration [40] . The drugs available for African sleeping sickness are pentamidine isethionate, suramin, melarsoprol, eflornithine, or nifurtimox-eflornithine combination treatment, the use of which depends on the disease stage and causative pathogen [41] . However, the clinical use of the current medications is compromised due to emerging strain-specific drug resistance, serious side-effects, high toxicity levels, and lengthy parental administration [42] . There is a critical need to develop new drugs for treatment of Chagas disease and sleeping sickness. The studies of ART and its derivatives on Trypanosome spp. are summarized in Table 2 .
In vitro studies
The drugs for in vitro studies include artesunate [43] , ART, artemisone, and 4-fluorophenyl-ART [31] ; the cell lines or cells used include African green monkey kidney cell line (Vero) [44] , the leukaemia cell line (HL-60) [45] , and cells from the peripheral blood of infected rat [43] . Artesunate can inhibit the replication of T. cruzi epimastigotes, amastigotes, and trypomastigotes in Vero cells in vitro [44] . Extracts (methanol extract and dichloromethane extract) from the leaves and aerial parts of four Artemisia species (Artemisia absinthium, A. abyssinica, A. afra, and A. annua) growing in Ethiopia have been tested against T. brucei brucei in vitro. The dichloromethane extract from A. abyssinica was the most active one (IC 50 = 19.13 g/mL), while ART from A. annua also showed anti-trypanosomal and cytotoxic activities (IC 50 = 35.91 g/mL), which may be due to lipophilic sesquiterpene lactones in the extract [45] . One of the mechanisms of trypanocidal activity is that lipophilic compounds such as lipophilic sesquiterpene lactones in the extract can increase the fluidity of the membranes: this results in uncontrolled efflux of ions and metabolites resulting in cell death [45] [46] [47] . Another mechanism of trypanocidal activity is the inhibition of ATPase in the presence of calcium; e.g., the inhibition of sarco/endoplasmic reticulum Ca 2+ -ATPase (SERCA) by inhibiting H + /K + -ATPase could be related to the inhibition of trypanosome growth [31] . The combination of artesunate and diminazene aceturate showed a complete clearance of T. brucei on day 5 in comparison of artesunate monotherapy on day 7 [43] . Studies showed that artesunate inhibits the replication of epimastigotes and intracellular amastigotes of three strains of T. cruzi originated in different regions of Latin America in vitro [44] . In addition, ART compounds inhibit T. cruzi growth in vitro and inhibit calciumdependent ATPase activity in T. cruzi membranes [31] .
In vivo studies
Mice [43, 44] and rats [48] have been used in these studies. It has been reported that 2.3 mg/kg and 4.6 mg/kg of artemether are able to suppress and reduce the number of T. brucei brucei parasites, and extend the lifespan of rats at the early and late stage treatment [48] . The lifespan of infected rats was extended to 19 days using a combination of halofantrine HCl with artemether compared to 14 days with artemether monotherapy [46] . Halofantrine HCl can form complex with heme-iron [49, 50] , which has lytic properties towards the parasite. The half-life of halofantrine HCl ranged from 1 to 4 days, thereby giving halofantrine HCl a high bioavailability [51] , which may be one of the factors that prolongs the lifespan of T. brucei-infected rats [48] . The reduction in parasitemia is probably due to the ability of artemether to form complex with heme that is believed to be toxic to the parasite [52, 53] . The clinical signs of dullness and paleness of mucous membrane on T. brucei-infected mice disappeared by both artemether and artesunate treatment. However, compared with artesunate, artemether is more effective as it clears the parasite completely from the body after 5 days of treatment [43] . In another study, artesunate alone was ineffective in reducing the parasites in T. cruzi-infected BALB/c mice and failed to cure the infection, suggesting that artesunate is unsuitable for in vivo treatment of T. cruzi infection [44] .
ART and its derivatives on T. gondii
T. gondii infects a large number of warm-blooded animals and is estimated to infect chronically up to one-third of the world's human population. Toxoplasmic encephalitis in patients with AIDS is a lifethreatening disease mostly due to reactivation of T. gondii cysts in the brain [54] . One of the current therapies for toxoplasmic infection is a combination of the drugs sulfadiazine and pyrimethamine [55] , which may cause side-effects including hematological reactions, hypersensitivity, and gastrointestinal disorders. The other available treatment is the combination of trimethoprim and sulfamethoxazole (cotrimoxazole), which is well tolerated and less toxic to hematopoiesis. However, these drugs can cross the placental barrier, so that its use is discouraged for pregnant women [56] . Moreover, these medicines have no effect on the tissue cysts of the parasite located predominantly in the brain and muscles [57] . It has been reported that medicinal plants can be used for toxoplasmosis as an alternative to standard drug therapy with reduced side effects. The studies on the effects of ART and its derivatives on T. gondii are summarized in Table 3 .
In vitro studies
RH strain of T. gondii and human foreskin fibroblast (HFF) cells were used in most of the in vitro studies. ART and its derivatives tested for their in vitro efficacy (IC 50 ) against T. gondii and cytotoxicity (TD 50 ) were measured to obtain the selectivity (SI) and/or therapeutic index (TI). Artesunate was proven to have much higher efficacy than current first-line drugs such as cotrimoxazole, pentamidine, pyrimethamine, and trimethoprim [58] . Intraparasitic heme activates ART and its derivatives to form reactive oxygen species (ROS) in the cytoplasm of host cells, which is then delivered across the parasitophorous vacuole membrane (PVM) to reach the tachyzoites within the PVM. ROS may damage the parasite by alkylating and poisoning one or more essential proteins and trigger the death of infected cells to control the growth of tachyzoites [59] . In addition, ART has the ability to trigger calcium-dependent secretion of microneme proteins in T. gondii parasites, affecting calcium homeostasis and signalling in the parasite, and acts as an inhibitor of SERCA [61] . Perturbation of Ca 2+ intake levels not only blocks parasite microneme secretion but also prevents motility and cell invasion of the parasite [69] . Arteether is lipophilic and therefore has activity against the central nervous system infection. At concentration ≥ 0.5 g/mL, arteether mediated reduction in incorporation of radiolabeled uracil into the nucleic acids of T. gondii tachyzoites [65] and showed higher efficacy than cycloguanil in inhibiting parasite growth. Eight thiazole derivatives and two carboxamide derivatives of dehydroartemisinin (DART) trioxane derivatives displayed effective growth inhibitory activities of T. gondii parasites, comparable to artemether in potency and over 100 times more potent than the front-line drug trimethoprim. The thiazoles were more effective than the other derivatives in inhibiting the growth of both the extracellular and intracellular parasites. Unexpectedly, two thiazole trioxanes (named compounds 5 and 6) were parasiticidal, both inhibited parasite replication irreversibly when parasites were exposed to 10 M of the drugs for 24 h, whereas the standard trioxane drugs (ART and artemether) were not parasiticidal [60] .
In vivo studies
CD1, OF1, and Kunming mice have been used in animal studies; extensive studies have shown that ART, artemether, arteether, artesunate, DHA, artimisone, artimiside, and other derivaties are active against T. gondii. In these studies, after treatment with ART or its derivatives, the total number of cysts per brain was counted from the research subjects to evaluate the efficacy of the drugs [62, 66, 68] . Using CD1 mice-infected with the PRU-Luc-GFP type II strain of T. gondii, approximately 20% of ART-treated mice survived the infection; however, 60% of the artemiside-treated mice and over 50% of the artemisone-treated mice survived the infection at 25 days p.i. In addition, compared with ART-treated mice, artemiside-and artemisone-treated mice developed significantly lower parasite burdens, e.g. luciferase (Luc) values in the brain at 9 days p.i. and significantly lower cyst numbers in the brain at 25 days p.i., indicating artemiside and artemisone have better antiparasitic efficacy on T. gondii than that of ART [66] .
ART and its derivatives on N. caninum and E. tenella
Neosporosis, caused by N. caninum, is a serious disease of dogs and livestock worldwide. Although no case of N. caninum infection has been reported in humans so far, the possibility of human N. caninum infection cannot be excluded due to its close phylogenetic relationship with T. gondii and its wide range of potential hosts [70] . Currently, there is no safe and effective chemotherapy for bovine neosporosis. Studies available for effective treatment of N. caninum using ART [71] and its derivatives (artemisone [72] [73] [74] , artemether [75] , GC007, and GC012 [74] ) are summarized in Table 4 .
An in vitro study showed that at a concentration of 10 or 20 g/mL, ART was able to reduce N. caninum and completely eliminated all microscopic foci of N. caninum in Vero cells by 11 days (third subculture) and at 1 g/mL, ART reduced N. caninum and completely eliminated all microscopic foci of N. caninum by 14 days (fourth subculture). The morphology and growth rate of the uninfected Vero cells treated with 20 g/mL of ART were normal, suggesting that the toxicity of ART is low. However, pretreatment of host cells or N. caninum tachyzoites with ART had no effect on intracellular replication of N. caninum tachyzoites [71] . An in vitro study showed that the parasites undergo apoptosis rather than uncontrolled cell death by long-term treatments using ART derivatives including artemisone, GC007, and GC012, which further proves the activity of ART derivatives in controlling N. caninum parasites [74] . However, artemiside and artemisone did not affect the cerebral parasite burden when assessed in a chronic infection model of N. caninum-infected BALB/c mice [74] . In another in vitro study, parasite growth inhibition can be as high as 92.1% when artemether concentration was 100 g/mL [75] .
In vivo studies
In an animal trial using gerbils (Meriones tristrami), only one out of 9 treated gerbils exhibited characteristic cerebral clinical signs and died 10 days after infection, indicating that artemisone plays a role in increasing the survivability of the infected hosts [72] . In another in vivo experiment, parasite burden in the brains of male BALB/c mice after artemisone treatment was lower than that by placebo, mefloquine, or artemiside treatment, suggesting possible efficacy of this drug; however the parasite burden in the lungs after artemisone treatment was higher than those of the above-mentioned drugs [73] . Thus, further in vivo investigations are needed for these drugs.
Avian coccidiosis is the most significant parasitic disease in the poultry industry [76] . Chickens are affected by seven different Eimeria spp. that infect the gut and are transmitted between birds via ingestion of infective oocysts. Several drugs such as nicarbazin, amprolium, quinolone, and ionophores, alone or in combination have proven to be an effective alternative against avian coccidiosis [77] . However, the emergence of drug-resistant strains, especially after a prolonged use of drugs, is a real problem. Based on the study on ART by del Cacho et al., there are significant reduction in oocyst output, mortality, and sporulation rate with an ART dose of 17 ppm compared to 10 ppm in E. tenella-infected white leghorn chicken [78] . By using immunofluorescence technique, SERCA in macrogametes was found to be inhibited by ART. Because SERCA plays a role in Ca 2+ homeostasis [79] , the inhibition of SERCA by ART impairs Ca 2+ -dependent ATPase and causes altered secretion of the wallforming bodies in macrogametes [78] . These findings suggested that ART can be used as an alternative anti-coccidial drug for avian coccidiosis, due to its anti-E. tenella activity on reducing intestinal lesions, oocyst output, and oocyst sporulation. The results from selected studies of ART and its derivatives on E. tenella are also summarized in Table 4 .
ART and its derivatives on A. castellanii and N. fowleri
Acanthamoeba spp. are the causative agents of Acanthamoeba keratitis, fatal granulomatous amebic encephalitis, and cutaneous infections [80] . Currently, no methods or single drug exists that can eliminate both cystic and trophozoite forms of Acanthamoeba. To treat the cyst form of Acanthamoeba that is highly resistant to therapy, a combination of agents is generally used [81] . An in vitro study shows that using 200 g/mL of artemether for 24 h against A. castellanii trophozoites causes a reduction in the number of trophozoites [82] . The effect toward trophozoites was minimal with slight changes of structure at 100 g/mL of artemether; there were a decreased number of trophozoites after 6 days of cultivation with 150 g/mL of artemether and there were no viable trophozoites after 5 days of cultivation with 200 g/mL of artemether. Based on the results, the amebicidal activities of artemether against A. castelanii trophozoites were found to be time-and dose-dependent. Among ART, artesunate, and DHA, DHA had the strongest amebicidal activity against Acanthamoeba, followed by artemether [82] . The inhibition of Acanthamoeba trophozoites by artemether may be due to its ability to downregulate phosphoglycerate dehydrogenase (PGDH) and phosphoserine aminotransferase (PSAT) in trophozoites. Based on the isobaric tags for relative and absolute quantitation (iTRAQ) analysis on Acanthomoeba treated with 200 g/mL of artemether, it was shown that the levels of PGDH and Tian et al. [85] DHA: dihydroartemisinin.
PSAT were decreased through inhibition of the l-serine biosynthesis pathway [82] . Further studies are needed to verify the efficacy and mechanisms of ART and its derivatives against Acanthamoeba infection. N. fowleri causes a fulminating and rapidly fatal primary amoebic meningoencephalitis (PAME) in humans [86] . The major problem of curing infections involving the pathogenic free-living amoebae is the lack of effective therapeutics [87] . ART, arteether, and artesunate have been tested against experimental PAME, and the efficacy of these compounds has been compared with amphotericin B, a standard drug for this pathogen. Compared to ART and its derivatives, 2.5 mg/kg of amphotericin B is effective in treating PAME of N. fowleri-infected Swiss mice. ART and artesunate showed only slight protection at 120 mg/kg by increasing the mean survival time to 1.9 and 2.6 days, respectively. Beta-arteether showed slightly better results at 120 mg/kg with an increase of the mean survival time to 5.3 days. However, all of the mice treated with the maximum tolerated dose (180 mg/kg) of ART and its derivatives suffered from PAME. This indicates that ART can increase the mean survival time but is unable to cure PAME caused by N. fowleri in Swiss mice [83] . Therefore, more studies are needed to confirm the effect of ART towards N. fowleri. The studies of ART and its derivatives on A. castellanii and N. fowleri are summarized in Table 5 .
ART and its derivatives on C. parvum and G. lamblia
Human cryptosporidiosis is mainly caused by C. hominis and C. parvum, which have been responsible for most of the outbreaks of Cryptosporidium described so far [88] . However, treatment faces challenges because of the limited options of using macrolides, paramomycin, nitazoxanide, and mirazid that have partial efficacy in reducing disease severity in immunocompromized individuals [89] . The use of ART towards C. parvum infection is not effective compared to macrolides antibiotics, and ART only caused a minor decrease in the mean number of oocyts at the highest concentration (2 mg/L). Thus, the inhibitory effects of ART against C. parvum showed limited effectiveness [84] . So far there are few reports on ART and its derivatives in the treatment of Cryptosporidium spp.; further studies are needed to explore their potential in treating this disease.
G. lamblia (syn. G. intestinalis, G. duodenalis) is one of the most frequent human intestinal protozoa causing giardiasis and infects hundreds of millions of people every year [90] . Metronidazole, tinidazole, mebendazole, albendazole, and furazolidone are effective anti-Giardia drugs, but have severe side effects and potential toxicity. Developing more effective and less toxic drugs against this protozoan parasite is necessary. The effects of DHA (LD 50 = 200 g/mL) at different time intervals on G. lamblia in vitro were investigated by using microscopy and cytometry techniques, and it was shown that DHA induced the changes in morphology and cell cycle state in G. lamblia [85] . The studies of ART and its derivatives on C. parvum and G. lamblia are summarized in Table 6 .
ART and its derivatives on Babesia spp.
Human babesiosis is a zoonotic disease caused by protozoan parasites of the Babesia genus. In humans, the most prevalent are infections caused by Babesia microti and less frequently, B. divergens, B. duncani, or B. venatorum [91] . Babesiosis shares many clinical features with malaria and can be fatal, particularly in the elderly and in immunocompromised individuals. Anti-malaria drugs and some antibiotics have been used in chemotherapy of babesiosis, including atovaquone, azithromycin, clindamycin, and quinine [92] . However, atovaquone-resistant genotype of B. gibsoni cytochrome b gene has been detected in three cases of B. gibsoni infections in Japan [93] . The investigations of ART and its derivatives on Babesia spp. are summarized in Table 7 .
In vitro studies
Different Babesia species (B. bovis, B. bigemina, B. caballi, B. equi, and B. gibsoni) have been tested with ART and its derivatives (DHA, artemisone, artesunate, and arteether). Artemisone induced dosedependent growth inhibition of both B. bovis and B. bigemina, of which B. bigemina appeared to be more sensitive to artemisone than B. bovis, as reflected by the different corresponding IC 50 [94] . A dose-and time-dependent inhibitory effect for artesunate was also reported against B. bovis. The study showed that artesunate was less effective than atovaquone and diminazene aceturate in inhibiting the growth of B. bovis [95] . Artesunate and pamaquine were more effective in suppressing parasitemia of B. equi than that of B. cablli, but pyrimethamine was more resistant to B. equi than that of B. caballi by comparing their IC 50 [96] . For B. gibsoni, artesunate was more effective in inhibiting the parasitemia than those of artemether, ART, and DHA but not atovaquone and diminazene [95] [96] [97] . In another study, it was reported that the single use of ART derivatives may only have low effectiveness, but the addition of lumefantrine to artemether may be effective for B. gibsoni infection [98] . Babesia parasites neither contain food vacuoles nor have hemozoin [99] . The absence of these organelles in Barbesia spp. may reduce the action of ART and its derivatives compared with Plasmodium spp. The mechanism of ART and its derivatives against Barbesia spp. may be related to the activation of the mitochondrial electron transport system resulting in ROS production [100] . The mechanism of action is still not yet fully understood.
In vivo studies
Various Babesia species (B. bovis, B. bigemina, B. microti, and B. equi) have been tested in different experimental animal models (calves, mice, and donkeys) for the anti-babesial effects of artemisone, artesunate, and arteether. The routes of administration are mostly intramuscular [95, 101] but also intraperitoneal [94] . Calves infected with B. bigemina and B. bovis were treated by artemisone (5 mg/kg) intraperitoneally and resulted in recovery of all animals, except for one B. bovis-infected calf. B. bigemina appeared to be more sensitive to artemisone than B. bovis as reflected by the differences of their IC 50 , although the treatment did not completely eliminate Babesia parasites. B. microti-infected BALB/c mice were intramuscularly treated by artesunate, which was not only inhibited the growth of the parasite but also delayed the increase of parasitemia, indicating that it can be a potential anti-B. microti agent [94] . Efficacy can be improved by combination with other babesiacide. It has been reported that splenectomised donkeys infected with B. equi were treated by intramuscular artesunate, arteether, or intramuscular arteether plus intravenous buparvaquone. In the artesunatetreated group, initial decrease in parasitaemia was observed, but the mean maximum parasitaemia increased dramatically between 16 and 19 days post-treatment; no recovery was observed in either the arteether-or buparvaquone-treated group. However, in the arteether-buparvaquone combination group, recovery was observed as parasites were cleared after 4-day treatment. Arteether and buparvaquone combination regimen also seemed to be safer than imidocarb alone in this study [101] .
Conclusion
NTDs are an extremely important issue facing global health care, which mostly affect people living in extreme poverty. ART, discovered by Youyou Tu and her colleaques in China more than 40 years ago, contributed greatly to treatment and control of malaria, and has led to Tu's sharing the 2015 Nobel Prize in Physiology or Medicine. Except for its well-known anti-malarial effect, ART and its derivatives also have anti-parasitic activities against many other parasitic infections, including protozoan parasites that infect humans such as Leishmania spp., Trypanosoma spp., A. castellanii, N. fowleri, and G. lamblia. In addition, these compounds are also active against protozoan parasites of both humans and domestic animals/livestocks such as T. gondii, C. parvum, and Babesia spp., and domestic animal/livestock protozoan parasites such as N. caninum (causing a serious disease of dogs and livestock, with the potential to infect humans) and Eimeria spp. (causing avian coccidiosis). The current first-line anti-protozoal drugs have limitions, including serious side-effects, toxicity, drug resistance, and even lack of effective or no chemotherapy. Thus, new drugs for the treatment of these protozoan infections are urgently needed. Greater emphasis should be placed on research and development of combination chemotherapies. ART or its derivatives are relaively low cost and low toxicity, and are promising anti-protozoal drugs alone or in combination with the current anti-protozoal drugs, which open new windows for combination therapies of parasitic protozoa. Arteether is a lipophilic compound that has good potential for therapies against protozoan infections involving the central nervous system such as T. gondii, A. castellanii, N. fowleri, and Trypanosoma spp. The emergence of drug-resistant strains of Leishmania and Trypanosoma make the current treatment face new challenges. So far there are no safe and effective chemotherapy for giardiasis and bovine neosporosis. Therefore, further efforts should focus on evaluation of the effectiveness of the compounds on these protozoan infections. Finally, the therapeutic mechanisms both in animals and in humans require more investigations. Therefore, understanding of structure-activity relationship of ART and its derivatives might lead to the development of effective drugs against parasitic protozoa.
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